Related references
Note: Only part of the references are listed.In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Robert T. Manguso et al.
NATURE (2017)
An immunogenic personal neoantigen vaccine for patients with melanoma
Patrick A. Ott et al.
NATURE (2017)
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Moshe Sade-Feldman et al.
NATURE COMMUNICATIONS (2017)
Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms
Dae-Sun Kim et al.
NATURE COMMUNICATIONS (2017)
Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma
Shawn T. Beug et al.
NATURE COMMUNICATIONS (2017)
The smac Mimetic BV6 improves nK cell-Mediated Killing of rhabdomyosarcoma cells by simultaneously Targeting Tumor and effector cells
Kyra Fischer et al.
FRONTIERS IN IMMUNOLOGY (2017)
Coinhibitory Pathways in Immunotherapy for Cancer
Susanne H. Baumeister et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 34 (2016)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors
Anthony W. Tolcher et al.
CLINICAL CANCER RESEARCH (2016)
IAP antagonists induce anti-tumor immunity in multiple myeloma
Marta Chesi et al.
NATURE MEDICINE (2016)
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Jesse M. Zaretsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
Michael S. Rooney et al.
CELL (2015)
Oral Debio 1143 (AT406), an Antagonist of Inhibitor of Apoptosis Proteins, Combined With Daunorubicin and Cytarabine in Patients With Poor-Risk Acute Myeloid Leukemia-Results of a Phase I Dose-Escalation Study
John F. DiPersio et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
c-IAP ubiquitin protein ligase activity is required for 4-1BB signaling and CD8+ memory T-cell survival
Maria Letizia Giardino Torchia et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effects of physiological and synthetic IAP antagonism on c-IAP-dependent signaling
A. J. Kocab et al.
ONCOGENE (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Inhibitors of apoptosis proteins (IAPs) are required for effective T-cell expansion/survival during antiviral immunity in mice
Ian E. Gentle et al.
BLOOD (2014)
Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors
Jeffrey R. Infante et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Smac mimetics and innate immune stimuli synergize to promote tumor death
Shawn T. Beug et al.
NATURE BIOTECHNOLOGY (2014)
Inhibitor of apoptosis protein (IAP) antagonists demonstrate divergent immunomodulatory properties in human immune subsets with implications for combination therapy
Ashley J. Knights et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Antagonists of IAP proteins as cancer therapeutics
Jasmin N. Dynek et al.
CANCER LETTERS (2013)
IAPs limit activation of RIP kinases by TNF receptor 1 during development
Maryline Moulin et al.
EMBO JOURNAL (2012)
Cellular Inhibitors of Apoptosis Are Global Regulators of NF-κB and MAPK Activation by Members of the TNF Family of Receptors
Eugene Varfolomeev et al.
SCIENCE SIGNALING (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Deletion of cIAP1 and cIAP2 in murine B lymphocytes constitutively activates cell survival pathways and inactivates the germinal center response
Sandra Gardam et al.
BLOOD (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Antagonists Induce a Conformational Change in cIAP1 That Promotes Autoubiquitination
Erin C. Dueber et al.
SCIENCE (2011)
IAP inhibitors enhance co-stimulation to promote tumor immunity
Michael Dougan et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Immune Therapy for Cancer
Michael Dougan et al.
ANNUAL REVIEW OF IMMUNOLOGY (2009)
Recruitment of the Linear Ubiquitin Chain Assembly Complex Stabilizes the TNF-R1 Signaling Complex and Is Required for TNF-Mediated Gene Induction
Tobias L. Haas et al.
MOLECULAR CELL (2009)
c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor α (TNFα)-induced NF-κB activation
Eugene Varfolomeev et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination
Mathieu J. M. Bertrand et al.
MOLECULAR CELL (2008)
Noncanonical NF-kappa B activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK
Brian J. Zarnegar et al.
NATURE IMMUNOLOGY (2008)
Both cIAP1 and cIAP2 regulate TNFα-mediated NF-κB activation
D. J. Mahoney et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Essential cytoplasmic translocation of a cytokine receptor-assembled signaling complex
Atsushi Matsuzawa et al.
SCIENCE (2008)
A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-α signaling
Alex Gaither et al.
CANCER RESEARCH (2007)
IAP antagonists induce autoubiquitination of c-IAPs, NF-κB activation, and TNFα-dependent apoptosis
Eugene Varfolomeev et al.
CELL (2007)
IAP antagonists target cIAP1 to induce TNFα- dependent apoptosis
James E. Vince et al.
CELL (2007)
Autocrine TNFα signaling renders human cancer cells susceptible to smac-mimetic-induced apoptosis
Sean L. Petersen et al.
CANCER CELL (2007)
Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma
Jonathan J. Keats et al.
CANCER CELL (2007)
Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma
Christina M. Annunziata et al.
CANCER CELL (2007)
XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome
Stephaine Rigaud et al.
NATURE (2006)
Inhibitor of apoptosis protein cIAP2 is essential for lipopolysaccharide-induced macrophage survival
D Conte et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Constitutive NF-κB activation by the t(11;18)(q21;q21) product in MALT lymphoma is linked to deregulated ubiquitin ligase activity
HL Zhou et al.
CANCER CELL (2005)
Posttranscriptional downregulation of c-IAP2 by the ubiquitin protein ligase c-IAP1 in vivo
DB Conze et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Characterization of XIAP-deficient mice
H Harlin et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Structural basis for the inhibition of caspase-3 by XIAP
SJ Riedl et al.
CELL (2001)
Share Paper
